FOXO factors: A matter of life and death

Future Oncology

Volumn 2, Issue 1, 2006, Pages 83-89

  Huang, Haojie ^a   Tindall, Donald J ^a  

^a Mayo Clinic   (United States)

Author keywords

Akt; FOXO proteins; FOXO1; FOXO3a; FOXO4; Phosphorylation; Prostate cancer; Proteasome degradation; PTEN; Skp2; Ubiquitination

Indexed keywords

BORTEZOMIB; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; S PHASE KINASE ASSOCIATED PROTEIN 2; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR FKHR; TRANSCRIPTION FACTOR FKHRL1; TRANSCRIPTION FACTOR FOXO; TRANSCRIPTION FACTOR FOXO4; UNCLASSIFIED DRUG;

ACETYLATION; APOPTOSIS; CANCER; CARCINOGENESIS; CELL FUNCTION; CELL PROLIFERATION; CELL PROTECTION; CLINICAL TRIAL; DNA DAMAGE; HUMAN; MULTIPLE MYELOMA; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; REVIEW; SEQUENCE HOMOLOGY; UBIQUITINATION;

ANIMALS; APOPTOSIS; CELL PROLIFERATION; DRUG DESIGN; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; NEOPLASMS; OXIDATIVE STRESS; PROTEIN PROCESSING, POST-TRANSLATIONAL;

EID: 33646782964     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/14796694.2.1.83     Document Type: Review

References (70)

1. Galili N, Davis RJ, Fredericks WJ, Mukhopadhyay S, Rauscher FJ 3rd. Emanuel BS et al.: Fusion of a fork head domain gene to PAX3 in the solid tumour alveolar rhabdomyosarcoma. Nature Genet. 5, 230-235 (1993).
2. Davis RJ, D'Cruz CM, Lovell MA, Biegel JA, Barr FG: Fusion of PAX7 to FKHR by the variant t(1;13)(p36;q14) translocation in alveolar rhabdomyosarcoma. Cancer Res. 54, 2869-7282 (1994).
3. Anderson MJ, Viars CS, Czekay S, Cavenee WK, Arden KC: Cloning and characterization of three human forkhead genes that comprise an FKHR-like gene subfamily. Genomics 47, 187-199 (1998)
4. Hillion J, Le Coniat M, Jonveaux P, Berger R, Bernard OA: AF6q21, a novel partner of the MLL gene in t(6;11) (q21;q23), defines a forkhead transcriptional factor subfamily. Blood 90, 3714-3719 (1997).
5. Corral J, Forster A, Thompson S et al.: Acute leukemias of different lineages have similar MLL gene fusions encoding related chimeric proteins resulting from chromosomal translocation. Proc. Natl Acad. Sci. USA 90, 8538-8542 (1993).
6. Parry P, Wei Y, Evans G: Cloning and characterization of the t(X;11) breakpoint from a leukemic cell line identify a new member of the forkhead gene family. Genes Chromosomes Cancer 11, 79-84 (1994).
7. Borkhardt A, Repp R, Haas OA et al.: Cloning and characterization of AFX, the gene that fuses to MLL in acute leukemias with a t(X;11)(q13;q23). Oncogene 14, 195-202 (1997).
8. Kaestner KH, Knochel W, Martinez DE: Unified nomenclature for the winged helix/forkhead transcription factors. Genes Dev. 14, 142-146 (2000).
9. Jacobs FM, van der Heide LP, Wijchers PJ, Burbach JP, Hoekman ME, Smidt MP: FoxO6, a novel member of the FoxO class of transcription factors with distinct shuttling dynamics. J. Biol. Chem. 278, 35959-35967 (2003).
10. Ogg S, Paradis S, Gottlieb S, Patterson GI et al.: The fork head transcription factor DAF-16 transduces insulin-like metabolic and longevity signals in C. elegans. Nature 389, 994-999 (1997).
11. Lin K, Dorman JB, Rodan A, Kenyon C: daf-16: An HNF-3/forkhead family member that can function to double the lifespan of Caenorhabditis elegans. Science 278, 1319-1322 (1997).
12. Honda Y, Honda S: The daf-2 gene network for longevity regulates oxidative stress resistance and Mn-superoxide dismutase gene expression in Caenorhabditis elegans. FASEB J. 13, 1385-1393 (1999).
13. Henderson ST, Johnson TE: daf-16 integrates developmental and environmental inputs to mediate aging in the nematode Caenorhabditis elegans. Curr. Biol. 11, 1975-1980 (2001).
14. Brunet A, Bonni A, Zigmond MJ et al.: Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 96, 857-868 (1999).
15. Kops GJ, de Ruiter ND, De Vries-Smits AM, Powell DR, Bos JL, Burgering BM: Direct control of the forkhead transcription factor AFX by protein kinase B. Nature 398, 630-634 (1999).
16. Biggs WH 3rd, Meisenhelder J, Hunter T, Cavenee WK, Arden KC: Protein kinase B/Akt-mediated phosphorylation promotes nuclear exclusion of the winged helix transcription factor FKHR1. Proc. Natl. Acad. Sci. USA 96, 7421-7426 (1999).
17. Tang ED, Nunez G, Barr FG, Guan KL: Negative regulation of the forkhead transcription factor FKHR by Akt. J. Biol. Chem. 274, 16741-16746 (1999).
18. Medema RH, Kops GJ, Bos JL, Burgering BM: AFX-like Forkhead transcription factors mediate cell-cycle regulation by Ras and PKB through p27kip1. Nature, 104, 782-787 (2000).
19. Nakamura N, Ramaswamy S, Vazquez F, Signoretti S, Loda M, Sellers WR: Forkhead transcription factors are critical effectors of cell death and cell cycle arrest downstream of PTEN. Mol. Cell. Biol. 20, 8969-8982 (2000).
20. Ramaswamy S, Nakamura N, Sansal I, Bergeron L, Sellers WR: A novel mechanism of gene regulation and tumor suppression by the transcription factor FKHR. Cancer Cell 2, 81-91 (2002).
21. Schmidt M, Fernandez de Mattos S, van der Horst A, Klompmaker R. Kops GJ, Lam EW et al.: Cell cycle inhibition by FoxO forkhead transcription factors Involves downregulation of cyclin D. Mol. Cell. Biol. 22, 7842-7852 (2002).
22. Alvarez B, Martinez AC, Burgering BM, Carrera AC: Forkhead transcription factors contribute to execution of the mitotic programme in mammals. Nature 413, 744-777 (2001).
23. Tran H, Brunet A, Grenier JM et al.: DNA repair pathway stimulated by the forkhead transcription factor FOXO3a through the Gadd45 protein. Science 296, 530-534 (2002).
24. Furukawa-Hibi Y, Yoshida-Araki K, Ohta T, Ikeda K, Motoyama N: FOXO forkhead transcription factors induce G(2)-M checkpoint in response to oxidative stress. J. Biol. Chem. 277, 26729-26732 (2002).
25. Nemoto S, Finkel T: Redox regulation of forkhead proteins through a p66shc-dependent signaling pathway. Science 295, 2450-2452 (2002).
26. Dijkers PF, Medema RH, Lammers JW, Koenderman L, Coffer PJ: Expression of the pro-apoptotic Bc1-2 family member Bim is regulated by the forkhead transcription factor FKHR-L1. Curr. Biol. 10, 1201-1204 (2000).
27. Modur V, Nagarajan R. Evers BM, Milbrandt J: FOXO proteins regulate tumor necrosis factor-related apoptosis inducing ligand expression. Implications for PTEN mutation in prostate cancer. J. Biol. Chem. 277, 47928-47937 (2002).
28. Gilley J, Coffer PJ, Ham J: FOXO transcription factors directly activate bim gene expression and promote apoptosis in sympathetic neurons. J. Cell Biol. 162, 613-622 (2003).
29. Puigserver P, Rhee J, Donovan J et al.: Insulin-regulated hepatic gluconeogenesis through FOXO1-PGC-1alpha interaction. Nature 423, 550-555 (2003).
30. Bois PR, Grosveld GC: FKHR (FOXO1a) is required for myotube fusion of primary mouse myoblasts. EMBO J. 22, 1147-1157 (2003).
31. Liu ZP, Wang Z, Yanagisawa H, Olson EN: Phenotypic modulation of smooth muscle cells through interaction of Foxo4 and myocardin. Dev. Cell 9, 261-270 (2005).
32. Wang CC, Gurevich I, Draznin B: Insulin affects vascular smooth muscle cell phenotype and migration via distinct signaling pathways. Diabetes 52, 2562-2569 (2003).
33. Accill D, Arden KC: FoxOs at the crossroads of cellular metabolism, differentiation, and transformation. Cell 117, 421-426 (2004).
34. Hosaka T, Biggs WH 3rd, Tieu D et al.: Disruption of forkhead transcription factor (FOXO) family members in mice reveals their functional diversification. Proc. Natl Acad. Sci. USA 101, 2975-2980 (2004).
35. Furuyama T, Kitayama K, Shimoda Y et al.: Abnormal angiogenesis in Foxo1 (Fkhr)-deficient mice. J. Biol. Chem. 279, 34741-34749 (2004).
36. Daly C, Wong V, Burova E et al.: Angiopoietin-1 modulates endothelial cell function and gene expression via the transcription factor FKHR (FOXO1). Genes Dev. 18, 1060-1071 (2004).
37. Castrillon DH, Miao L, Kollipara R, Horner JW, DePinho RA: Suppression of ovarian follicle activation in mice by the transcription factor Foxo3a. Science 301, 215-218 (2003).
38. Nakae J, Park BC, Accili D: Insulin stimulates phosphorylation of the forkhead transcription factor FKHR on serine 253 through a Wortmannin-sensitive pathway. J. Biol. Chem. 274, 15982-15985 (1999).
39. Rena G, Guo S, Cichy SC, Unterman TG, Cohen P: Phosphorylation of the transcription factor forkhead family member FKHR by protein kinase B. J. Biol. Chem. 274, 17179-17183 (1999).
40. Guo S, Rena G, Cichy S, He X, Cohen P, Unterman T: Phosphorylation of serine 256 by protein kinase B disrupts transactivation by FKHR and mediates effects of insulin on insulin-like growth factor-binding protein-1 promoter activity through a conserved insulin response sequence. J. Biol. Chem. 274, 17184-17192 (1999).
41. Brunet A, Sweeney LB, Sturgill JF et al.: Stress-dependent regulation of FOXO transcription factors by the SIRT1 deacetylase. Science 303, 2011-2015 (2004).
42. Sunayama J, Tsuruta F, Masuyama N, Gotoh Y: JNK antagonizes Akt-mediated survival signals by phosphorylating 14-3-3. J. Cell Biol. 170, 295-304 (2005).
43. Plas DR, Thompson CB: Akt activation promotes degradation of tuberin and FOXO3a via the proteasome. J. Biol. Chem. 278, 12361-12366 (2003).
44. Matsuzaki H, Daitoku H, Hatta M, Tanaka K, Fukamizu A: Insulin-induced phosphorylation of FKHR (Foxo1) targets to proteasomal degradation. Proc. Natl Acad. Sci. USA 100, 11285-11290 (2003).
45. Huang H, Regan KM, Wang F et al.: Skp2 inhibits FOXO1 in tumor suppression through ubiquitin-mediated degradation. Proc. Natl Acad. Sci. USA 102, 1649-1654 (2005).
46. Mamillapalli R, Gavrilova N, Mihaylova VT et al.: PTEN regulates the ubiquitin-dependent degradation of the CDK inhibitor p27(KIP1) through the ubiquitin E3 ligase SCF(SKP2). Curr. Biol. 11, 263-267 (2001).
47. Lin J, Adam RM, Santiestevan E, Freeman MR: The phosphatidylinositol 3-kinase pathway is a dominant growth factor-activated cell survival pathway in LNCaP human prostate carcinoma cells. Cancer Res. 59, 2891-2897 (1999).
48. Murillo H, Huang H, Schmidt LJ, Smith DI, Tindall DJ: Role of PI3K signaling in survival and progression of LNCaP prostate cancer cells to the androgen refractory state. Endocrinologv 142, 4795-4805 (2001).
49. Huang H, Muddiman DC, Tindall DJ: Androgens negatively regulate forkhead transcription factor FKHR (FOXO1) through a proteolytic mechanism in prostate cancer cells. J. Biol. Chem. 279, 13866-13877 (2004).
50. Nasrin N, Ogg S, Cahill CM et al.: DAF-16 recruits the CREB-binding protein coactivator complex to the insulin-like growth factor binding protein 1 promoter in HepG2 cells. Proc. Natl Acad. Sci, USA 97, 10412-10417 (2000).
51. Fukuoka M, Daitoku H, Hatta M, Matsuzaki H, Umemura S, Fukamizu A: Negative regulation of forkhead transcription factor AFX (Foxo4) by CBP-induced acetylation. Int. J. Mol. Med. 12, 503-508 (2003).
52. Tissenbaum HA, Guarente L: Increased dosage of a sir-2 gene extends lifespan in Caenorhabditis elegans. Nature 410, 227-230 (2001).
53. Motta MC, Divecha N, Lemieux M et al.: Mammalian SIRT1 represses forkhead transcription factors. Cell 116, 551-563 (2004).
54. van der Horst A, Tertoolen LG, de Vries-Smits LM, Frye RA, Medema RH, Burgering BM: FOXO4 is acetylated upon peroxide stress and deacetylated by the longevity protein hSiR2(SIRT1). J. Biol. Chem. 279, 28873-28879 (2004).
55. Daitoku H, Hatta M, Matsuzaki H et al.: Silent Information regulator 2 potentiates Foxo1-mediated transcription through its deacetylase activity. Proc. Natl Acad. Sci. US4 101, 10042-10047 (2004).
56. Matsuzaki H, Daitoku H, Hatta M, Aoyama H, Yoshimochi K, Fukamizu A: Acetylation of Foxo1 alters its DNA-binding ability and sensitivity to phosphorylation. Proc. Natl Acad. Sci. USA 102, 11278-11283 (2005).
57. Xia SJ, Pressey JG, Barr FG: Molecular pathogenesis of rhabdomyosarcoma. Cancer Biol. Ther. 1, 97-104 (2002).
58. Lagutina I. Conway SJ, Sublett J, Grosveld GC: Pax3-FKHR knock-in mice show developmental aberrations but do not develop tumors. Mol. Cell. Biol. 22, 7204-7216 (2002).
59. Anderson MJ, Shelton GD, Cavenee WK, Arden KC: Embryonic expression of the tumor-associated PAX3-FKHR fusion protein interferes with the developmental functions of Pax3. Proc. Natl Acad. Sci. USA 98, 1589-1594 (2001).
60. Relaix F, Polimeni M, Rocancourt D, Ponzetto C, Schafer BW, Buckingham M: The transcriptional activator PAX3-FKHR rescues the defects of Pax3 mutant mice but induces a myogenic gain-of-function phenotype with ligand-independent activation of Met signaling in vivo. Genes Dev. 17, 2950-2965 (2003).
61. Fredericks WJ, Galili N, Mukhopadhyay S et al.: The PAX3-FKHR fusion protein created by the t(2;13) translocation in alveolar rhabdomyosarcomas is a more potent transcriptional activator than PAX3. Mol. Cell. Biol. 15, 1522-1535 (1995).
62. Zhang L, Wang C: PAX3-FKHR transformation increases 26 S proteasome-dependent degradation of p27Kip1, a potential role for elevated Skp2 expression. J. Biol. Chem. 278, 27-36 (2003).
63. Keller C, Arenkiel BR, Coffin CM, E1-Bardeesy N, DePinho RA, Capecchi MR: Alveolar rhabdomyosarcomas in conditional Pax3:Fkhr mice: co-operativity of Ink4a/ARF and Trp53 loss of function. Genes Dev. 18, 2614-2626 (2004).
64. Bois PR, Izeradjene K, Houghton PJ, Cleveland JL, Houghton JA, Grosveld GC: FOXO1a acts as a selective tumor suppressor in alveolar rhabdomyosarcoma. J. Cell Biol. 170, 903-912 (2005).
65. Papandreou CN, Daliani DD, Nix D et al.: Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer. J. Clin. Oncol. 22, 2108-2121 (2004).
66. Yang G, Ayala G, De Marzo A, Tian W, Frolov A, Wheeler TM et al.: Elevated Skp2 protein expression in human prostate cancer: association with loss of the cyclin-dependent kinase inhibitor p27 and PTEN and with reduced recurrence-free survival. Clin. Cancer Res. 8, 3419-3426 (2002).
67. Ben-Izhak O, Lahav-Baratz S, Meretyk S et al.: Inverse relationship between Skp2 ubiquitin ligase and the cyclin dependent kinase inhibitor p27Kip1 in prostate cancer. J. Biol. 170, 241-245 (2003).
68. Latres E, Chiarle, R, Schulman BA et at.: Role of the F-box protein Skp2 in lymphomagenesis. Proc. Natl Acad Sci. USA 98, 2515-2520 (2001).
69. Signoretti S, Di Marcotullio, L, Richardson A et al.: Oncogenic role of the ubiquitin ligase subunit Skp2 in human breast cancer. J. Clin. Invest. 110, 633-641 (2002).
70. Gstaiger M, Jordan R, Lim MJ et al.: Skp2 is oncogenic and overexpressed in human cancers. Proc. Natl Acad. Sci. USA 98, 5043-5048 (2001).